Diagnostic approach to von Willebrand disease

Blood

Volumn 125, Issue 13, 2015, Pages 2029-2037

  Ng, Christopher ^a,b   Motto, David G ^c   Paola, Jorge Di ^a,b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c Bloodworks Northwest Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; PROTEIN BINDING;

ANAMNESIS; AUTOSOMAL RECESSIVE INHERITANCE; BLOOD CELL COUNT; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISULFIDE BOND; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC SCREENING; HEMOPHILIA B; HETEROZYGOTE; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; PROTHROMBIN TIME; REVIEW; SCREENING TEST; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 1C; VON WILLEBRAND DISEASE TYPE 2A; VON WILLEBRAND DISEASE TYPE 2B; VON WILLEBRAND DISEASE TYPE 2M; VON WILLEBRAND DISEASE TYPE 2N; CLASSIFICATION; DIAGNOSTIC PROCEDURE; GENETICS; HEMORRHAGE; MASS SCREENING; METABOLISM; PROCEDURES; PROTEIN MULTIMERIZATION; SKIN DISEASES; TRENDS; VON WILLEBRAND DISEASES;

CLINICAL LABORATORY TECHNIQUES; GENETIC TESTING; HEMORRHAGE; HUMANS; MASS SCREENING; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SKIN DISEASES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84926142676     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-528398     Document Type: Review

References (70)

1. Haberichter SL, Castaman G, Budde U, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood. 2008;111(10): 4979-4985.
2. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest. 1985;76(4):1491-1500.
3. Federici AB, Bader R, Pagani S, Colibretti ML, De Marco L, Mannucci PM. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size. Br J Haematol. 1989;73(1):93-99.
4. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78(6):1456-1461.
5. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factorcleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662-1666.
6. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
7. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174.
8. Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost. 2011;37(5): 528-534.
9. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-898.
10. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2): 454-459.
11. Sadler JE, Rodeghiero F; ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost. 2005;3(4):775-777.
12. Tosetto A, Rodeghiero F, Castaman G, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-773.
13. Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost. 2011;9(6): 1143-1148.
14. Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123(26):4037-4044.
15. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-121.
16. O'Brien SH. Bleeding scores: are they really useful? Hematology Am Soc Hematol Educ Program. 2012;2012:152-156.
17. James PD, Paterson AD, Notley C, et al Association of Hemophilia Clinic Directors of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost. 2006;4(4):783-792.
18. Cariappa R, Wilhite TR, Parvin CA, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol. 2003;25(6):474-479.
19. Dean JA, Blanchette VS, Carcao MD, et al. von Willebrand disease in a pediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost. 2000;84(3):401-409.
20. Quiroga T, Goycoolea M, Muñoz B, et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost. 2004;2(6): 892-898.
21. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost. 2003;90(3):483-490.
22. Castaman G, Tosetto A, Goodeve A, et al. The impact of bleeding history, von Willebrand factor and PFA-100(-) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol. 2010; 151(3):245-251.
23. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost. 1999;82(1):35-39.
24. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695.
25. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, Schlammadinger A, Mazurier C, Deckmyn H. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost. 2000;83(1): 107-113.
26. Chen D, Daigh CA, Hendricksen JI, et al. A highlysensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry. J Thromb Haemost. 2008;6(2): 323-330.
27. Flood VH, Gill JC, Morateck PA, et al. Gain-offunction GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011;117(6): e67-e74.
28. Flood VH, Gill JC, Morateck PA, et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010;116(2):280-286.
29. Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453-465.
30. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013;122(23):3735-3740.
31. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012;10(7): 1425-1432.
32. Flood VH, Gill JC, Friedman KD, et al Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013;59(4): 684-691.
33. Favaloro EJ. Von Willebrand factor collagenbinding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey. Semin Thromb Hemost. 2002;28(2):191-202.
34. Flood VH, Lederman CA, Wren JS, et al. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010;8(6):1431-1433.
35. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. 2006;108(10):3344-3351.
36. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980;302(19):1047-1051.
37. Miller JL, Kupinski JM, Castella A, Ruggeri ZM. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease. J Clin Invest. 1983; 72(5):1532-1542.
38. Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W. A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity. Blood. 1982; 60(1):201-207.
39. Flood VH, Friedman KD, Gill JC, et al. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013;121(18):3742-3744.
40. Laffan M, Brown SA, Collins PW, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004;10(3):199-217.
41. Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease-single center comparison of four different assays. Thromb Haemost. 2000;84(6):1127-1128.
42. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D. Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF: Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood. 1999;93(12):4277-4283.
43. Eikenboom JC, Matsushita T, Reitsma PH, et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 1996;88(7): 2433-2441.
44. Sadler JE, Budde U, Eikenboom JCJ, et al Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
45. Sztukowska M, Gallinaro L, Cattini MG, et al. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol. 2008;143(1): 107-114.
46. Haberichter SL, Christopherson PA, Flood VH, et al. Critical importance of VWF propeptide (VWFpp) in the diagnosis of type 1 von Willebrand disease (VWD) [abstract]. Blood. 2013;122(21). Abstract 331.
47. Desch KC, Ozel AB, Siemieniak D, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA. 2013; 110(2):588-593.
48. Van Schie MC, Wieberdink RG, Koudstaal PJ, et al. Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: the Rotterdam Study. J Thromb Haemost. 2012; 10(4):550-556.
49. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008; 14(2):171-232.
50. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol. 2001;14(2):365-379.
51. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest. 1986;77(3): 947-951.
52. Kroner PA, Kluessendorf ML, Scott JP, Montgomery RR. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets. Blood. 1992;79(8): 2048-2055.
53. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(3):526-534.
54. Hamilton A, Ozelo M, Leggo J, et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost. 2011;105(3):501-508.
55. Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14(2):337-347.
56. Quiroga T, Goycoolea M, Belmont S, et al. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemost. 2014;12(8):1238-1243.
57. Favaloro EJ, Bonar RA, Meiring M, et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res. 2014;134(2):393-403.
58. Kitchen S, Jennings I, Woods TA, Kitchen DP, Walker ID, Preston FE. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemost. 2006;32(5):492-498.
59. Hayes TE, Brandt JT, Chandler WL, et al. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost. 2006;32(5):499-504.
60. Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia. 2014;20(1): 147-153.
61. Costa-Pinto J, Pérez-Rodríguez A, del C Goméz-del-Castillo M, et al. Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia. 2014;20(4):559-567.
62. Bowyer AE, Shepherd F, Kitchen S, Makris M. A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. Thromb Res. 2011; 127(4):341-344.
63. Vinayagam S, Simons LR, Chowdary P, Thurlow P, Brooks SV, Riddell AF. Evaluation of a rapid von Willebrand factor activity latex immuno assay for monitoring of patients with von Willebrand disease (VWD) receiving DDAVP or VWF replacement therapy. Haemophilia. 2014;20(4): e304-e310.
64. Lasne D, Dey C, Dautzenberg M-D, et al. Screening for von Willebrand disease: contribution of an automated assay for von Willebrand factor activity. Haemophilia. 2012; 18(3):e158-e163.
65. th IS Factor VIII/von Willebrand factor, plasma (07/316). J Thromb Haemost. 2012;10(5): 959-960.
66. Eikenboom J, Van Marion V, Putter H, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006;4(4):774-782.
67. Budde U, Schneppenheim R, Eikenboom J, et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008;6(5):762-771.
68. Hansen RR, Tipnis AA, White-Adams TC, Di Paola JA, Neeves KB. Characterization of collagen thin films for von Willebrand factor binding and platelet adhesion. Langmuir. 2011; 27(22):13648-13658.
69. Neeves KB, Onasoga AA, Hansen RR, et al. Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. PLoS ONE. 2013;8(1):e54680.
70. Grabowski EF, Curran MA, Van Cott EM. Assessment of a cohort of primarily pediatric patients with a presumptive diagnosis of type 1 von Willebrand disease with a novel high shear rate, non-citrated blood flow device. Thromb Res. 2012;129(4):e18-e24.